Bomedemstat (IMG-7289), an LSD1 Inhibitor, Manages the Signs and Symptoms of Essential Thrombocythemia (ET) While Reducing the Burden of Cells Homozygous for Driver Mutations

• Published in: Blood Vol. 142; no. Supplement 1; p. 747
• Main Authors: Goethert, Joachim R., Gill, Harinder, Palandri, Francesca, Ross, David M., Cochrane, Tara, Larsen, Stephen R., Halpern, Anna B., Shortt, Jake, Rossetti, James M., Liang, James, Marchetti, Monia, Wilson, Andrew J., Innes, Andrew, Hanna, Merit, Stevenson, William S., Vannucchi, Alessandro M., Kleppe, Maria, Natsoulis, Georges, Harrison, Claire N, Rienhoff Jr, Hugh Young
• Format: Journal Article
• Language: English
• Published: Elsevier Inc 02.11.2023

The ultimate goal in the treatment of ET is to eliminate mutant cells with the capacity to both proliferate and self-renew. Lysine-specific demethylase-1, LSD1, is an enzyme critical for regulating the proliferation of hematopoietic stem cells and the maturation of progenitors (Sprussel et al. 2012)...